Phosphorylated Signal Transducer and Activator of Transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma

Li,Wei; Wei,Qiang; Liang,Jianbo

doi:10.3892/mmr.2014.2046

Phosphorylated Signal Transducer and Activator of Transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma

Authors:
- Wei Li
- Qiang Wei
- Jianbo Liang
View Affiliations

Affiliations: Department of Urology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China, Department of Pathology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China
Published online on: March 13, 2014 https://doi.org/10.3892/mmr.2014.2046
Pages: 1929-1934

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the expression status of Janus kinase (JAK)‑Signal Transducer and Activator of Transcription (STAT) in renal cell carcinoma and benign renal tissue, and identify a potential biomarker for interferon (IFN) response prediction. A total of 32 specimens of human renal cell carcinoma and 10 specimens of benign renal tissue were harvested from surgically removed kidneys. The expression levels of JAK‑STAT were determined by immunohistochemical staining and quantitative polymerase chain reaction. Furthermore, the expression levels of JAK‑STAT in renal cell carcinoma tissues that were stimulated with IFN‑α were quantified by western blot analysis. The positive expression rates of JAK1, STAT1 and phosphorylated (P)‑STAT1 in the renal cell carcinomas were significantly lower than that in the benign renal tissues (25.0, 31.2, and 12.5% vs. 70.0, 50.0, and 70.0%, respectively; P<0.05). The relative expression levels of JAK1 (0.696±0.102) and STAT1 mRNA (0.341±0.068) in the tumor tissue were lower than those in the benign tissue (0.957±0.103 and 0.547±0.082, respectively; P<0.05). IFN stimulation enhanced the expression levels of P‑STAT1 in the renal cell carcinoma tissues, and enhancement of the P‑STAT1 expression levels was associated with tumor relapse and metastasis. In conclusion, P‑STAT1 is a potential predictor of IFN response in patients with advanced renal cell carcinoma.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S and Kiemeney LA: The epidemiology of renal cell carcinoma. Eur Urol. 60:615–621. 2011. View Article : Google Scholar : PubMed/NCBI
3	Athar U and Gentile TC: Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 15:3954–3966. 2008.PubMed/NCBI
4	Jurado JM, Zarcos I, Delgado M, Blancas I, Legerén M and García-Puche JL: Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report. Oncol Lett. 5:1382–1384. 2013.PubMed/NCBI
5	Tanriverdi O: Review on targeted treatment of patients with advanced-stage renal cell carcinoma: a medical oncologist’s perspective. Asian Pac J Cancer Prev. 14:609–617. 2013.PubMed/NCBI
6	Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
7	Shang D, Liu Y, Ito N, Kamoto T and Ogawa O: Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance. Cancer Sci. 98:1259–1264. 2007. View Article : Google Scholar : PubMed/NCBI
8	Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, et al; Japan Immunotherapy SNPs-Study Group for Kidney Cancer. STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma. Eur Urol. 63:745–752. 2013.
9	Masuda A, Kamai T, Abe H, Arai K and Yoshida K: Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma? Biomed Res. 30:171–176. 2009. View Article : Google Scholar : PubMed/NCBI
10	Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th ed. Springer Verlag; New York, NY: pp. 547–560. 2009
11	Na Yanqun, Ye Zhangqun and Sun Guang: The CUA Guideline for Urological Disease. People’s Health Publishing House; Beijing: pp. 4–16. 2011, (In Chinese).
12	Chen L, Zhu YY, Zhang XJ, Wang GL, Li XY, He S, Zhang JB and Zhu JW: TSPAN1 protein expression: a significant prognostic indicator for patients with colorectal adenocarcinoma. World J Gastroenterol. 15:2270–2276. 2009. View Article : Google Scholar : PubMed/NCBI
13	Zeng Z, Que T, Zhang J and Hu Y: A study exploring critical pathways in clear cell renal cell carcinoma. Exp Ther Med. 7:121–130. 2014.PubMed/NCBI
14	Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, et al: Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem. 272:28779–28785. 1997. View Article : Google Scholar : PubMed/NCBI
15	Brinckmann A, Axer S, Jakschies D, Dallmann I, Grosse J, Patzelt T, Bernier T, et al: Interferon-alpha resistance in renal carcinoma cells is associated with defective induction of signal transducer and activator of transcription 1 which can be restored by a supernatant of phorbol 12-myristate 13-acetate stimulated peripheral blood mononuclear cells. Br J Cancer. 86:449–455. 2002.
16	Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA and Abbruzzese A: Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol. 202:323–335. 2005. View Article : Google Scholar : PubMed/NCBI
17	Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA and Belldegrun AS: Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 174:466–472. 2005. View Article : Google Scholar
18	Noguchi Y, Kurokawa MS, Okuse C, Matsumoto N, Nagai K, Sato T, Arito M, et al: Serum peptides, represented by complement 3f des-arginine, are useful for prediction of the response to pegylated interferon-α plus ribavirin in patients with chronic hepatitis C. Hepatol Res. 43:743–756. 2013.PubMed/NCBI
19	Azuma T, Matayoshi Y, Nagase Y and Oshi M: Neutrophil number after interferon-alfa treatment is an independent predictive marker of overall survival in metastatic renal cell carcinoma. Clin Genitourin Cancer. 10:180–184. 2012. View Article : Google Scholar : PubMed/NCBI